Saag Kenneth G
Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, 1813 Sixth Avenue South, Birmingham, AL 35294-3296, USA.
Endocrinol Metab Clin North Am. 2003 Mar;32(1):135-57, vii. doi: 10.1016/s0889-8529(02)00064-6.
Therapeutic use of glucocorticoids can lead to many well-known adverse events. Of all potential serious side effects, glucocorticoid-induced osteoporosis (GIOP) is one of the most devastating complications of protracted glucocorticoid therapy in rheumatoid arthritis. GIOP is the most common form of drug-induced osteoporosis. Although much has been written about the association of glucocorticoids with bone disease among patients with chronic inflammatory conditions, many issues remain unsettled. This article focuses on areas of continued controversies, including the epidemiology and pathogenesis of GIOP, specification of a "safe" dose, methods for diagnosis of GIOP, and an evidence-based approach for GIOP prevention.
糖皮质激素的治疗应用可导致许多众所周知的不良事件。在所有潜在的严重副作用中,糖皮质激素诱导的骨质疏松症(GIOP)是类风湿关节炎长期糖皮质激素治疗最具破坏性的并发症之一。GIOP是药物性骨质疏松症最常见的形式。尽管关于慢性炎症性疾病患者中糖皮质激素与骨病的关联已有大量著述,但许多问题仍未解决。本文聚焦于持续存在争议的领域,包括GIOP的流行病学和发病机制、“安全”剂量的确定、GIOP的诊断方法以及基于证据的GIOP预防方法。